Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Pharma 'on track' for first half

Wed, 25th Jul 2018 10:15

(Sharecast News) - Cancer-focused pharmaceutical company Midatech Pharma has remained "on track" to deliver financial results for the first half of the calendar year in line with market expectations, and was still exploring options about how to meet its cash flow needs.Midatech expects total gross product revenues to grow approximately 16% to £5.8m.The firm noted that sales for the second half of 2017 represented 56% of the year's gross product sales and anticipates a similar split in 2018 as a result of continued sales growth at "historic rates".Midatech noted that clinical trials for two of its key oncology drug candidates, the sustained release product Q-Octreotide MTD201 and MTX110, had progressed well, along with clinical trial preparation work on MTD119, the firm's advanced liver cancer drug candidate which received Orphan Drug Designation earlier in the year.The AIM-quoted group said it "remains on track" to announce results from the initial phase of its ongoing in-human study of Q-Octreotide MTD201, designed for the treatment of acromegaly and carcinoid cancer, by the end of the year.Midatech highlighted that it was continuing to review a "range of options" to meet its cash flow needs, including non-dilutive financing and other strategic alternatives.Chief executive Dr Craig Cook said, "I am pleased to report a strong trading update for the first half of the year, with continued sales growth in our US business and significant progress made in our key clinical programmes, MTD201 and MTX110.""There is renewed momentum throughout the group as we progress towards the key value inflection points for our clinical pipeline over the next eighteen months, and we remain focused on bringing our innovative and potentially life-changing therapies to market in areas of significant unmet need," added Cook.As of 1020 BST, Midatech shares had dipped 1.75% to 28p.
More News
23 Apr 2018 11:02

Midatech Pharma 2017 Loss Narrows On Costs And Impairments Fall

LONDON (Alliance News) - Midatech Pharma PLC said Monday its 2017 loss narrowed on lower costs and reduced impairments as its approaches 2018 with a number of key "inflection" points for

Read more
15 Mar 2018 12:36

Midatech Pharma CEO Phillips To Step Down, COO Cook Steps Up

LONDON (Alliance News) - Pharmaceutical firm Midatech Pharma PLC said Thursday its Chief Executive Jim Phillips will leave the company after five years at the who is departing

Read more
22 Nov 2016 13:29

Midatech Pharma receives upfront access fee

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma said it has received an upfront technology access fee and option payment of £450,000. This was under the terms of the exclusive licence granted to Emergex Vaccines Ltd. This licence covered the use of Midatech's prop

Read more
15 Nov 2016 12:04

Midatech Pharma chooses MTR104 for liver cancer treatment

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma has selected its candidate compound MTR104 to take into a formal IND-enabling programme during 2017. This would be followed by human studies planned for 2018, the company said. "The programme is focused on advanced l

Read more
31 Oct 2016 09:39

BROKER RATINGS SUMMARY: HSBC Raises IAG To Hold From Reduce

Read more
11 Oct 2016 10:30

Midatech To Raise GBP14 Million Via Placing And Open Offer (ALLISS)

Read more
30 Sep 2016 08:41

Midatech Says Trials Of Drug Using Its Gold Nanoparticles Commence

Read more
2 Sep 2016 12:07

Midatech Pharma's revenues increases due to US sales

(ShareCast News) - Midatech Pharma's half-year revenues increased significantly, with management sounding an optimistic note regarding the potential of the company´s research and development programmes. For the six months ended 30 June, revenue increased significantly to £3.8m from £320,000 in the s

Read more
7 Jul 2016 09:05

Midatech-Cardiff University Collaboration Gets Diabetes Grant

Read more
27 Jun 2016 11:29

Midatech Pharma Issues Final Shares To Settle Q Chip Acquisition (ALLISS)

Read more
18 May 2016 09:39

Midatech Signals Further Focus On "Better Suited" Oncology Treatments

Read more
11 May 2016 08:49

Midatech Pharma Trading Ahead Of Expectations On Strong Revenue Growth

Read more
26 Apr 2016 09:27

Midatech Pharma Gets Positive Data From Q-Octreotide Trial

Read more
21 Apr 2016 07:55

Midatech Pharma Sees Positive Dosing Data In Uveitis Programme

Read more
13 Apr 2016 08:24

Midatech Loss Widens On Acquisition Costs, But Revenue Surges

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.